In this deliverable we present a preliminary policy brief outlining the policy implications directlyrelated to BRYOMOLECULES implementation and expected outcomes. These implications arepresented under different contextual groups, covering the current regulatory frameworks for theproduction of bioactive molecules from engineered species, the EU plans and goals forbiodiversity conservation and circular economy implementation, as well as social andconsumers acceptances of biotechnology-based products.This first policy brief has the role of providing short summaries for the policymakers in the fieldsof biodiversity, bryophyte conservation and the environmental sustainability of circular economyand biotechnology-based metabolic engineering processes for added-value secondarymetabolite production. A final policy brief will be produced at the end of the project (M36) drawingfrom the project outcomes generated and translating them into actionable policyrecommendations. The final policy brief will provide a comprehensive overview of the policyimplications associated to BRYOMOLECULES outputs and a set of recommendations for thepolicymakers. Do you want to know more about BRYOMOLECULES? Visit our project website: https://bryomolecules.eu
Stefania Vitale (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: